Phase 2
N=33
Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach
Parkinson · Tremor
Bottom Line
View on ClinicalTrials.gov: NCT02419313 ↗Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Mar 2016
Primary outcome: Primary: Unified Parkinsons Disease Rating Scale (UPDRS) Tremor Scale — 0; 8 participants — p=0.0007
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- incobotulinumtoxinA (Drug); Saline (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Yale University
- Primary completion
- Sep 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Unified Parkinsons Disease Rating Scale (UPDRS) Tremor Scale |
0; 8 | 0.0007 sig |
| SECONDARY Number of Patients Whose Patient Global Impression of Change (PGIC) Improved |
0; 10 | 0.0008 sig |
| SECONDARY Patients With Significant Improvement in Unified Parkinsons Disease Rating Tremor Scale |
0; 8 | 0.0105 sig |
Summary
The scientific aim of this study is to investigate the efficacy and safety of incobotulinumtoxinA (Xeomin-Merz Pharmaceuticals) in the tremor of Parkinson"s disease. Our hypothesis is that injection of Xeomin into the muscles of arm, forearm and hand decreases the tremor amplitude and frequency leading to improvement of the patient"s function.
Eligibility Criteria
Inclusion Criteria.
- Age more than 18 years
- Both sexes
- all races/ethnic groups.
- Meeting the clinical diagnosis of Parkinson's disease with presence of moderate to severe Parkinson tremor that is refractory to standard medical treatments and which limits the patient"s functionality and/or poses significant discomfort.
- Subjects who are able to read, speak, and understand English.
Exclusion Criteria.
- Existing significant acute medical condition (i.e. cardiovascular, endocrine, hematologic, neoplastic, infectious, or autoimmune disorders) or significant swallowing or breathing difficulties.
- Pregnancy or planned pregnancy (determined by urine pregnancy test).
- Active breast feeding.
- Enrollment in any clinical trial (currently or within the past 3 months) in which treatments are imposed by a protocol.
- Any subject for whom botulinum toxin treatment would be contraindicated; known allergy or sensitivity to medication.
- Subjects who are younger than 18 years of age. Neuromuscular-junction disorders.
- Evidence of acute pathology in neuro-imaging.
- Axis I diagnosis determined by a neurologist or psychiatrist.
- Use of Anesthetic medications within two weeks and corticosteroid injections within 4 weeks of enrollment.
- Those who received botulinum toxin injections in the past 4 months.
Data sourced from ClinicalTrials.gov (NCT02419313). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.